Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.77 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.77 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | APEX1 | P27695 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.58 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.58 |
| ▸ | TUBB | P07437 | 2/20 | 0.58 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.58 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.58 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.58 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.58 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10307813 | 0.95 | ALOX5 (0.76) | ALOX5OR51E2CYP19A1CYP3A4CYP1A2 | |
| SCHEMBL10307534 | 0.95 | ALOX5 (0.76) | ALOX5OR51E2CYP19A1CYP3A4CYP1A2 | |
| SCHEMBL10307751 | 0.94 | ALOX5 (0.89) | ALOX5OR51E2CYP19A1CYP3A4CYP1A2 | |
| SCHEMBL10307539 | 0.93 | ALOX5 (0.68) | ALOX5OR51E2CYP19A1CYP3A4CYP1A2 | |
| SCHEMBL4002776 | 0.92 | ALOX5 (0.67) | ALOX5OR51E2CYP19A1CYP3A4CYP1A2 | |
| SCHEMBL13811080 | 0.90 | ALOX5 (0.63) | ALOX5OR51E2CYP19A1CYP3A4CYP1A2 | |
| SCHEMBL18396941 | 0.89 | IAPP (0.69) | ALOX5OR51E2CYP19A1CYP3A4CYP1A2 | |
| Tetrahydrocurcumin SCHEMBL284877 | 0.87 | ALOX5 (1.00) | ALOX5OR51E2CYP3A4CYP1A2TSHR | |
| Tetrahydrocurcumin SCHEMBL29372158 | 0.87 | ALOX5 (1.00) | ALOX5OR51E2CYP3A4CYP1A2TSHR | |
| Tetrahydrocurcumin SCHEMBL29370299 | 0.87 | ALOX5 (1.00) | ALOX5OR51E2CYP3A4CYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3763419-A1 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | Anji Pharma (US) LLC (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-2661266-B1 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ANJI PHARMA (US) LLC (US) | 2020-09-16 | — | — | EP | disclosed |
| US-10610500-B2 | Chemosensory receptor ligand-based therapies | ANJI PHARMA (US) LLC (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190038576-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2019-02-07 | — | — | US | disclosed |
| US-9962344-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170020829-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2017-01-26 | — | — | US | disclosed |
| US-9463170-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20150265555-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2015-09-24 | — | — | US | disclosed |
| US-9050292-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20140030332-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20120177730-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-6875426-B2 | Self-tanning composition containing a tetrahydrocurcuminoid and a self-tanning agent | L'OREAL (FR) | 2005-04-05 | — | — | US | disclosed |
| US-6872401-B2 | Cosmetic/dermatological compositions comprising a tetrahydrocurcuminoid and an amide oil | L'OREAL (FR) | 2005-03-29 | — | — | US | disclosed |
| US-20040009200-A1 | Cosmetic/dermatological compositions comprising a tetrahydrocurcuminoid and an amide oil | SOCIETE L'OREAL S.A. (FR) | 2004-01-15 | — | — | US | disclosed |
| US-20030228268-A1 | Self-tanning composition containing a tetrahydrocurcuminoid and a self-tanning agent | SOCIETE L'OREAL S.A. (FR) | 2003-12-11 | — | — | US | disclosed |
| EP-1348424-A1 | Self-tanning composition containing a tetrahydrocurcumine derivative and a self-tanning agent | L'OREAL (FR) | 2003-10-01 | — | — | EP | disclosed |
| EP-1348418-A1 | Cosmetical or dermatological composition containing a tetrahydrocurcumin derivative and an oil bearing an amide group | L'OREAL (FR) | 2003-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120177730-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | ALOX5 2867/4885OR51E2 130/4885CYP19A1 2622/4885 |
| US-10610500-B2 | Chemosensory receptor ligand-based therapies | TAS1R2, TAS2R1, GPR119 | ALOX5 2867/4885OR51E2 130/4885CYP19A1 2622/4885 |
| US-20150265555-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | ALOX5 2867/4885OR51E2 130/4885CYP19A1 2622/4885 |
| US-20030228268-A1 | Self-tanning composition containing a tetrahydrocurcuminoid and a self-tanning agent | TYR, TES, TERT | ALOX5 963/4885OR51E2 3141/4885CYP19A1 68/4885 |
| US-20170020829-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | ALOX5 2867/4885OR51E2 130/4885CYP19A1 2622/4885 |
| US-20190038576-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | ALOX5 2867/4885OR51E2 130/4885CYP19A1 2622/4885 |
| US-20040009200-A1 | Cosmetic/dermatological compositions comprising a tetrahydrocurcuminoid and an amide oil | KRT18, DHCR24, FABP4 | ALOX5 39/4885OR51E2 3668/4885CYP19A1 198/4885 |
| US-20140030332-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | ALOX5 2867/4885OR51E2 130/4885CYP19A1 2622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.